Last updated on January 2020

Study of Tumour Focused Radiotherapy for Bladder Cancer

Brief description of study

Bladder cancer is the seventh most common cancer in the UK, with 10,399 new cases diagnosed in 2011. In a quarter of these cases the cancer has infiltrated the muscular wall of the bladder (muscle invasive) and is life threatening. This type of bladder cancer is usually treated either with surgical removal of the bladder, or daily radiotherapy treatment (high strength xrays which kill cells), given every day for 4 or 7 weeks. RAIDER will investigate methods which have the potential to improve how well this radiotherapy works.

RAIDER is based on a study of novel radiotherapy techniques which was conducted at a single UK NHS Trust. Bladder radiotherapy is normally delivered using a single plan throughout treatment and treats the whole bladder with the same radiotherapy dose. In adaptive radiotherapy the delivery plan is chosen from 3 possible plans. In cancer (tumour) focused radiotherapy, the highest dose of the radiotherapy is aimed at the tumour within the bladder.

In RAIDER, 240 participants with muscle invasive bladder cancer will be in one of 3 treatment

  1. standard whole bladder radiotherapy
  2. standard dose tumour focused adaptive radiotherapy
  3. dose escalated tumour boost adaptive radiotherapy

Participants will visit the hospital 4 weeks, 3, 6, 9, 12, 18 and 24 months after radiotherapy and annually thereafter to check whether the cancer has returned and to receive treatment for any symptoms they may be experiencing.

RAIDER aims to confirm in a multicentre setting that novel techniques allow a higher radiotherapy dose than standard to be reliably targeted at the tumour within the bladder and to check that the long term side effects of the treatment are acceptable. If this is the case, results of RAIDER will be used to develop a study to establish whether dose escalated radiotherapy is better at treating bladder cancer than standard dose.

Detailed Study Description

RAIDER has a two stage design. Stage 1 will establish the feasibility of delivering DART in a multi-centre setting, and stage 2 will establish the toxicity of DART. 72 patients will be recruited in stage 1, with an additional 168 patients in stage 2.

Both fractionation regimens in standard use in UK are included - 32f and 20f. Participants will be permitted to receive concomitant chemotherapy. Primary endpoints will be assessed in each fractionation cohort separately with the flexibility to drop either a fractionation cohort or an experimental treatment group (on advice of Independent Data Monitoring Committee) following completion of stage 1.

Clinical Study Identifier: NCT02447549

Find a site near you

Start Over

Austin Hospital

Melbourne, Australia
  Connect »

Auckland Hospital

Auckland, New Zealand
  Connect »

Christchurch Hospital

Christchurch, New Zealand
  Connect »


Hamilton, New Zealand
  Connect »


Tauranga, New Zealand
  Connect »

Ipswich Hospital

Ipswich, United Kingdom
  Connect »

Barts Health NHS Trust

London, United Kingdom
  Connect »

Ayr Hospital

Ayr, United Kingdom
  Connect »

Belfast City Hospital

Belfast, United Kingdom
  Connect »

West Suffolk Hospital

Bury St Edmunds, United Kingdom
  Connect »

Addenbrooke's Hospital

Cambridge, United Kingdom
  Connect »

Cheltenham General Hospital

Cheltenham, United Kingdom
  Connect »

Western General Hospital

Edinburgh, United Kingdom
  Connect »

St Luke's Cancer Centre

Guildford, United Kingdom
  Connect »

Royal Marsden NHSFT

London, United Kingdom
  Connect »

Royal Oldham Hospital

Manchester, United Kingdom
  Connect »

Mount Vernon Cancer Centre

Northwood, Middlesex, United Kingdom
  Connect »

Peterborough City Hospital

Peterborough, United Kingdom
  Connect »

Queen Alexandra Hospital

Portsmouth, United Kingdom
  Connect »

Royal Preston Hospital

Preston, United Kingdom
  Connect »

Mid Yorkshire Hospitals

Wakefield, United Kingdom
  Connect »